



1646  
#9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: FREDEKING *et al.*  
Serial No.: 10/038,557  
Filed: January 3, 2002

For: *COMPOSITIONS AND METHODS  
FOR TREATING HEMORRHAGIC  
VIRUS INFECTIONS AND OTHER  
DISORDERS*

Art Unit: Unassigned  
Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office

P.O. Box 2327

Arlington, VA 22202, on this date.

03/05/02  
Date

*Maritza O'Neill*  
Maritza O'Neill

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement and Form PTO-1449 (1 page) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

- ☒ The Commissioner is hereby authorized to charge any fee, including any submitted herewith if the attached check(s) is in the wrong amount or otherwise improper or missing, that may be due in connection with this and the attached papers, or with this application during its entire pendency to or to credit any overpayment to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE LLP

By: \_\_\_\_\_

Stephanie Seidman  
Registration No. 33,779

Attorney Docket No. 24881-301D  
Address all correspondence to:  
Stephanie Seidman, Esq.  
HELLER EHRMAN WHITE & McAULIFFE LLP  
4350 La Jolla Village Drive, 7th Floor  
San Diego, California 92122-1246  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
E-mail: sseidman@HEWM.com



RECEIVED  
MAR 14 2002  
TECH CENTER 1600/290

Applicant: FREDEKING *et al.*  
Serial No.: 10/038,557  
Filed: January 3, 2002

For: *COMPOSITIONS AND METHODS FOR  
TREATING HEMORRHAGIC VIRUS  
INFECTIONS AND OTHER DISORDERS*

Art Unit: Unassigned  
Examiner: Unassigned

I hereby certify that this paper and the  
attached papers are being deposited with  
the United States Postal Service as first  
class mail in an envelope addressed to:  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202, on this date

03/05/02  
Date

Maritza O'Neill

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 2327  
Arlington, VA 22202

Dear Sir:

Since this Supplemental Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98. Form PTO-1449 (1 page) is provided herewith. In accordance with 37 C.F.R. § 1.98(d), copies of the references marked with an asterisk are not provided herewith, as they have been previously provided in connection with application U.S. Serial No. 09/562,979, which is relied upon for an earlier filing date in accordance with 35 U.S.C. § 120.

The documents listed on the Form PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark

**U.S.S.N. 10/038,557**

**FREDEKING *et al.***


**Supplemental Information Disclosure Statement**

Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

  
Stephanie Seidman  
Registration No. 33,779

Attorney Docket No. 24881-301D

**Address all correspondence to:**

Stephanie Seidman, Esq.

HELLER EHRMAN WHITE & McAULIFFE LLP

4350 La Jolla Village Drive, 7th Floor

San Diego, California 92122-1246

Telephone: (858) 450-8400

Facsimile: (858) 587-5360

E-mail: sseidman@HEWM.com

FORM PTO-1449 (Modified)



LIST OF PATENTS AND PUBLICATIONS FOR  
APPLICANT'S INFORMATION DISCLOSURE  
STATEMENT

ATTY. DOCKET NO.  
24881-301D

SERIAL NO.  
10/038,557

APPLICANT  
FREDEKING *et al.*

FILING DATE  
January 3, 2002

GROUP  
1646

\* Copies of articles not enclosed.

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
*	AA	0	0	2	2	6	0	8	2/21/02	Duncan, <i>et al.</i>	514	152	05/05/00

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
none														

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

*	AB	Mäurer <i>et al.</i> , "Genetic variation at position -1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis", <i>J. of Neuroimmunology</i> , <u>104</u> :98-100 (2000)
*	AC	Nagelkerken, L., "Role of Th1 and Th2 cells in autoimmune demyelinating disease" <i>Brazilian Journal of Medical and Biological Research</i> , <u>31</u> :55-60 (1998)
*	AD	Özenci <i>et al.</i> , "Multiple Sclerosis: Levels of Interleukin-10-Secreting Blood Mononuclear Cells are Low in Undertreated Patients but Augmented During Interferon- $\beta$ -1b Treatment" <i>Scand. J. Immunol.</i> , <u>49</u> :554-561 (1991)
*	AE	Salmaggi <i>et al.</i> , "Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?", <i>J. Neurol.</i> , <u>243</u> :13-17

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC VIRUS INFECTIONS AND OTHER DISORDERS**